Artificial intelligence–assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies
22% efficiency gains and 40% fewer second opinion requests
The study’s outcomes demonstrated significant time savings with AI, including reduced reading times, improved laboratory efficiency, shorter turnaround times, and a notable decrease in IHC and second opinion requests.
Artificial intelligence–assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies
Published in Virchows Archiv
Catarina Eloy, Ana Marques, João Pinto, Jorge Pinheiro, Sofia Campelos, Mónica Curado, João Vale & António Polónia
Virchows Arch 482, 595–604 (2023)
ABOUT THIS STUDY
Artificial intelligence–assisted cancer diagnosis improves the efficiency of pathologists in prostatic biopsies
The study was designed by Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup) to assess how the use of Paige Prostate Detect and Paige Prostate Grade & Quantify could impact pathologist performance in a fully digital laboratory.
AI Used: Paige Prostate Suite
BY THE NUMBERS
The Results
A group of 4 generalist pathologists evaluated a retrospective cohort of 105 consecutive prostate needle biopsy whole-slide images in 2 phases: first without support from AI, and then after a washout period, assisted by AI. Performance characteristics including diagnostic accuracy and concordance, slide read time, IHC requests, and second opinion requests were evaluated.
21.9% reduction in slide reading times in benign and malignant cases
32.4% fewer atypical small acinar proliferation (ASAP) reported
24.7% reduction in IHC requests for cancer cases increase in pathologist specificity
17.3% reduction in IHC requests for non-cancer cases
39.2% reduction in second opinion requests
The synergic usage of Paige Prostate significantly decreases the time for reporting, IHC and second opinion requests and preserves tissue by representing cancer in small biopsies while maintaining highly accurate diagnostic standards in prostate cancer.